• Pharma

    Pharma

  • Energy

    Energy

  • Cyber

    Cyber

  • Defence

    Defence

  • Automotive

    Automotive

  • Aviation

    Aviation

Pharma

Retinal disease pharmaceutical sales will reach $17.38bn in 2020, a new DART study predicts

A new report by DART forecasts the overall world market for treating age-related macular degeneration (AMD or ARMD), diabetic retinopathy (DR) and other disorders of the retina will reach $17.38bn in 2020. That revenue forecast and others appear in Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF, published in July 2016.

This updated report provides the detailed analysis and opportunities in wet AMD, dry AMD and diabetic retinopathy (DR) sector. Many pharmaceutical companies are aiming to develop more effective drugs with different mechanism of action to treat wet AMD. At present there are no drugs in the market for dry AMD, although dry age-related macular degeneration (dAMD) is more common than wet AMD (wAMD). Currently, there are many drugs in the pipeline for the treatment of dry AMD. The breakthrough in the dry AMD sector is expected to happen in next 5 years, DART estimates.

There are unmet needs remaining in retinal diseases sector and pharmaceutical companies are aiming to meet these needs within the next ten years. Companies seek to improve upon the standard of care (SOC) treatment for wAMD, whilst developing new therapies for dry AMD and other retinal diseases such as diabetic retinopathy (DR) and retinal vein occlusion (RVO). The retinal disease overall market is expected to keep growing for the next 10 years as current promising pipeline candidates attain approvals. This report provides an analysis of this fast-growing market in 2015, as well as forecasting the prospects for revenue growth over the period 2016-2026.

Shruti Tayal, a pharmaceutical industry analyst in DART, said: “In 2015, Eylea is leading the therapeutic market of AMD and other retinal diseases. Avastin is challenging both Lucentis and Eylea for drug volume sales and price. DART expects the retinal market to reach revenues of $17.38bn with a CAGR of 10.2% by the end of 2020. Few products in the pipeline are waiting for approval to enter the wet AMD market. The status of dry AMD submarket may change due to the promising results shown by few drugs in the pipeline. In the second half of the forecast period, the market will face competition from generic drugs as branded drugs will lose patent exclusivity and there will be uptake of new products such as new combination therapies.”

This updated report shows 10-years revenue forecasts to 2026 at overall world market, disease submarkets, product (brand) and national market level. The study gives revenue predictions to 2026 for four therapeutic submarkets at world level:

  • Wet age-related macular degeneration (wAMD)
  • Dry AMD (dAMD)
  • Diabetic retinopathy (DR)
  • Other retinal diseases (grouped forecast).

The study also provides revenues and forecast of five prominent drugs to 2026: Lucentis, Eylea, Avastin, Visudyne and Jetrea.

Research, data and analyses cover activities of Roche, Novartis, Bayer, Regeneron, Allergan, Valeant and other developers, manufacturers and marketers of ophthalmic pharmaceuticals. Analyses cover leaders and other organisations for retinal medicines.

This new study also discusses R&D and commercial news, shows two interviews and predicts revenues to 2026 in 11 leading national markets. The work analyses the United States (US), EU5 (Italy, Spain, Germany, the UK and France), Japan, BRIC countries (Brazil, Russia, India and China), and the Rest of the World.

Retinal Diseases: Wet and Dry AMD, Diabetic Retinopathy Market 2016-2026: Aflibercept, Ranibizumab, Bevacizumab, Verteporfin, Ocriplasmin, Anti-VEGF, Anti-PDGF adds to DART’s analyses on industries and markets in healthcare. Together those studies cover pharmaceuticals, diagnostics, medical devices, outsourced services and biotechnologies commercial potentials.

Copyright © DART Markets. All rights reserved.

Cookie policy

We use cookies on our website. By using our website you agree to this Policy and you consent to our use of cookies in accordance with the terms of this Policy.

About Cookies
A cookie is a small file which asks permission to be placed on your computer's hard drive. Once you agree, the file is added and the cookie helps analyse web traffic or lets you know when you visit a particular site. Cookies allow web applications to respond to you as an individual. The web application can tailor its operations to your needs, likes and dislikes by gathering and remembering information about your preferences.

There are two main kinds of cookies: "session" cookies and "persistent" cookies. Session cookies only last for the duration of users using the website and are deleted from your computer when you close your browser, whereas persistent cookies outlast user sessions and remain stored on your computer until deleted, or until they reach their expiry date.

Cookies help us provide you with a better website, by enabling us to monitor which pages you find useful and which you do not.

Cookies do not contain any information that personally identifies you, a cookie in no way gives us access to your computer or any information about you.

You can choose to accept or decline cookies. Most web browsers automatically accept cookies, but you can usually modify your browser setting to decline cookies if you prefer. This may prevent you from taking full advantage of the website.

Cookies on this Website
We use persistent cookies on this website to provide links to social network sharing services, and to update you on our most popular content.

Third Party Cookies
We do not use third party cookies.

Google Analytics
We also use cookies to help us improve the website's usability and for marketing purposes. We may also use cookies to identify which pages are being used. This helps us analyse data about webpage traffic and improve our website in order to tailor it to customer needs. We only use this information for statistical analysis purposes and then the data is removed from the system.

For this purpose we use Google Analytics. Google Analytics generates statistical and other information about website use by means of cookies, which are stored on users' computers. The information generated relating to our website is used to create reports about the use of the website. Google will store and use this information. Google's privacy policy is available at www.google.com/privacypolicy.html.

This website cookies policy template is based on a free document supplied by The Legal Stop Limited through its website www.thelegalstop.co.uk.

If you have any questions about privacy please contact us.